Skip to main content

Prof. Dr. Jonathan Schmid-Burgk

Member, Steering-Committee Member

Institute of Clinical Chemistry & Clinical Pharmacology

Medical Faculty, University of Bonn University Hospital of Bonn Venusberg - Campus 1 53127 Bonn

Jonathan.Schmid-Burgk@ukbonn.de

+49 228 28751650

Website

Innate immune responses can be life-saving or life-threatening. Our group studies immune signaling pathways at the molecular and cellular level, for which we are developing new technologies like CRISPaint and in-cellulo sequencing. Besides that, we work on algorithms to search for unknown diversity in sequencing data in order to characterize self-diversifying systems.

Jonathan Schmid-Burgk

Recent publications

  • The PRECISE European initiative for cancer-vulnerability mapping and prediction.

    Nature genetics

    Authors: Francesco Iorio, Mathew J Garnett, Pedro Beltrao, Maximilian Billmann, Larissa Bless, Christoph Bock, Michael Boutros, Alejandra Bruna, Piero Carninci, Giovanni Ciriello, Isidro Cortés-Ciriano, Giuseppina D'Alessandro, Roberta Esposito, Stefania Faletti, Emanuel Gonçalves, Syed Haider, Nereo Kalebic, Manuel Kaulich, Giuseppe Leuzzi, Nuria Lopez-Bigas, Christopher J Lord, Evangelia Petsalaki, Stephen Pettitt, Ludovica Proietti, Roland Rad, Nevenka Radic, Colm J Ryan, Jonathan L Schmid-Burgk, Sumana Sharma, Andrea Sottoriva, Christopher Tape, Livio Trusolino, Jolanda van Leeuwen, David Walter, Lodewyk Wessels

    View this publication
  • NIS-Seq enables cell-type-agnostic optical perturbation screening.

    Nature biotechnology

    Authors: Caroline I Fandrey, Marius Jentzsch, Peter Konopka, Alexander Hoch, Katja Blumenstock, Afraa Zackria, Salie Maasewerd, Marta Lovotti, Dorothee J Lapp, Florian N Gohr, Piotr Suwara, Jędrzej Świeżewski, Lukas Rossnagel, Fabienne Gobs, Maia Cristodaro, Lina Muhandes, Rayk Behrendt, Martin C Lam, Klaus J Walgenbach, Tobias Bald, Florian I Schmidt, Eicke Latz, Jonathan L Schmid-Burgk

    View this publication
  • Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma.

    Molecular therapy. Nucleic acids

    Authors: Christian Grützner, Yu Pan Tan, Patrick Müller, Thais M Schlee-Guimaraes, Marius Jentzsch, Jonathan L Schmid-Burgk, Marcel Renn, Rayk Behrendt, Gunther Hartmann

    View this publication